Highlights of the Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program

Day 1 :
WEDNESDAY, APRIL 29, 2026
08:30 - 09:30
REGISTRATION AND MORNING REFRESHMENTS
09:30 - 09:40
OPENING ADDRESS
09:40 - 10:05
GUT MICROBIAL METABOLITES AS MODULATORS OF NEUROINFLAMMATION IN ALZHEIMER’S DISEASE
Vasu Gautam
Norton Healthcare

Vasu Gautam

Norton Healthcare

  • Investigating gut metabolites that modulate neuroinflammation and amyloid, shaping therapy in AD
  • Identifying specific metabolites and mapping their linkage to defined gut microbes in AD
  • Proposing customizable probiotics for Alzheimer’s patients using metabolite–microbe signals
10:05 - 10:10
Q&A SESSION ON GUT METABOLITES AND ALZHEIMER’S DISEASE
10:10 - 10:40
SPEED NETWORKING SESSION
  • Exchange business cards and get connected in short one-to-one meetings
  • Start the conversation to arrange a more formal meeting later on in the conference
  • Share your professional background and discuss your biggest business issues – don't forget your business cards
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:30
PANEL DISCUSSION ON METABOLIC MEDICINE
11:30 - 11:55
OPTIMIZING GLP-1 AGONIST THERAPY THROUGH METHYLATION PATHWAY ASSESSMENT
Charles Sailey
Molecular Testing Labs

Charles Sailey

Molecular Testing Labs

  • Introducing gene-guided GLP-1 optimization using methylation variants like MTHFR and COMT
  • Enhancing metabolic outcomes by correcting inefficiencies in one-carbon nutrient pathways
  • Demonstrating improved GLP-1 efficacy and detox response through precision supplementation
11:55 - 12:00
Q&A SESSION ON PRECISION GENETICS AND GLP-1 RESPONSE
12:00 - 12:25
GENERATIVE AI-DRIVEN CARDIOMETABOLIC SMALL MOLECULE DRUG DISCOVERY AT INSILICO MEDICINE
Carol Satler
Insilico Medicine

Carol Satler

Insilico Medicine

  • Harnessing generative AI to design long-acting GLP-1R drugs for obesity and cardiometabolic disease
  • Developing AI-generated small molecules for obesity, diabetes, and associated cardiovascular disease
  • Demonstrating GLP-1R candidates with strong in vitro and in vivo profiles for single and combo use
12:25 - 12:30
Q&A SESSION ON AI-DRIVEN CARDIOMETABOLIC DRUG DESIGN
12:30 - 13:30
NETWORKING LUNCH AND VISITING THE OBESITY MEDICINE EXHIBITION
13:30 - 13:55
THE MIND/BODY PROBLEM – METABOLIC SYNDROME AND COGNITIVE DECLINE
Steve Winshel
FULLFILL

Steve Winshel

FULLFILL

  • Clarifying the strong links between metabolic dysfunction and cognitive impairments
  • Highlighting complications due to the late detection of cognitive decline in patients
  • Showcasing innovative early detection tools to prevent irreversible brain changes
  • Integrating mind-body approaches to address both metabolic and cognitive issues
13:55 - 14:00
Q&A SESSION ON LINKING METABOLISM AND BRAIN HEALTH
14:00 - 14:30
RESERVED PRESENTATION
14:30 - 15:00
RESERVED PRESENTATION
15:00 - 15:30
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:30 - 15:55
UNLOCKING NATURAL WEIGHT-REGULATING BIOLOGY THROUGH LEPTIN SENSITIZATION
Teo Uysal
ERX Pharmaceuticals

Teo Uysal

ERX Pharmaceuticals

  • Delving into leptin's pivotal role in weight regulation and obesity treatment
  • Uncovering unique biological mechanisms for enhanced efficacy and muscle preservation
  • Presenting promising initial findings from a Phase 1 study of a novel leptin sensitizer
15:55 - 16:00
Q&A SESSION ON LEPTIN SENSITIZATION IN OBESITY TREATMENT
16:00 - 16:25
ENABLING DEVICE SOLUTIONS FOR UNMET NEEDS IN BIOTHERAPIES
Asmita Khanolkar
SMC® Ltd.

Asmita Khanolkar

SMC® Ltd.

  • Highlighting novel methods for drug-device-delivery optimization and assessment
  • Introducing an autoinjector simulator to evaluate pharmacokinetics and dynamics
  • Accelerating early evaluation and speed to clinics for biologics with unique needs
16:25 - 16:30
Q&A SESSION ON ENABLING DEVICE SOLUTIONS IN BIOTHERAPIES
16:30 - 16:55
MAPPING THE HUMAN ENZYME–METABOLITE INTERACTOME TO UNCOVER MECHANISMS OF METABOLIC REGULATION, DISEASE, AND THERAPEUTIC OPPORTUNITIES
Kevin Hicks
University of Utah

Kevin Hicks

University of Utah

  • Mapping enzyme–metabolite interactions (EMIs) with MIDAS to reveal metabolic regulation and disease
  • Combining equilibrium dialysis and LC–MS to discover ligands for soluble and membrane proteins
  • Showcasing novel EMI networks and allosteric regulators with therapeutic potential
16:55 - 17:00
Q&A SESSION ON THE HUMAN ENZYME–METABOLITE INTERACTOME
17:00 - 18:00
NETWORKING DRINKS RECEPTION
Day 2 :
THURSDAY, APRIL 30, 2026
09:00 - 09:30
MORNING REFRESHMENTS
09:30 - 09:40
OPENING ADDRESS
09:40 - 10:05
ENSURING ACCESS AND SUPPORT IN OBESITY CARE
Sansei Fowler
CVS Health

Sansei Fowler

CVS Health

  • Enhancing patient access to obesity treatments through optimal payer coverage strategies
  • Coordinating care models for GLP-1 therapy for comprehensive support to improved outcomes
  • Forecasting future trends in obesity treatment by analyzing drug pipelines and the role of PBMs in care
10:05 - 10:10
Q&A SESSION ON THE ACCESS AND SUPPORT IN OBESITY TREATMENT
10:10 - 10:35
NA-931: AN ORAL QUADRUPLE RECEPTOR AGONIST FOR WEIGHT LOSS WITHOUT MUSCLE LOSS
Lloyd Tran
Biomed Industries, Inc.

Lloyd Tran

Biomed Industries, Inc.

  • Describing the mechanism of action of this oral quadruple receptor agonist
  • Summarizing topline Phase 1 and Phase 2 clinical trial results on the safety and efficacy of NA-931
  • Reporting significant weight loss with no muscle loss or major GI-related adverse events
10:35 - 10:40
Q&A SESSION ON NA-931 AND ADVANCES IN WEIGHT MANAGEMENT
10:40 - 11:10
RESERVED PRESENTATION
11:10 - 11:30
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:30 - 11:55
METABOLIC ARCHITECTURE: THE PHYSIOLOGY OF A HIGH-RETENTION CLINICAL ECOSYSTEM
Naomi Parrella
Classic Care MD

Naomi Parrella

Classic Care MD

  • Harmonizing pharmacotherapy, surgery and lifestyle in a metabolic loop that preserves lean mass
  • Standardizing care with the ABCDE framework so teams deliver consistent metabolic plans at scale
  • Achieving a solvent, high-reliability clinic model with >65% retention and employer-aligned growth
11:55 - 12:00
Q&A SESSION ON HIGH-RETENTION METABOLIC CARE MODELS
12:00 - 12:25
EXPLORING INNOVATIVE TECHNOLOGIES IN THE FIGHT AGAINST OBESITY
Ashley Zehnder
Fauna Bio

Ashley Zehnder

Fauna Bio

  • Discussing rising global obesity rates and the urgent need for innovative solutions
  • Examining the role of muscle-preserving agents in improving metabolic health during weight loss
  • Highlighting recent technological and biomedical advancements in obesity treatment strategies
12:25 - 12:30
Q&A SESSION ON USING MUSCLE PRESERVATION FOR OBESITY TREATMENTS
12:30 - 12:55
TRANSFORMING OBESITY RESEARCH WITH METABOLIC TRACER TECHNOLOGIES
Natalie Marchi
Metabolic Solutions

Natalie Marchi

Metabolic Solutions

  • Tracking patient fat synthesis, oxidation and energy use directly with metabolic tracer assays
  • Using tracer-based case studies that add valuable endpoints in metabolic disease trials
  • Implementing tracer protocols into preclinical and clinical workflows without disrupting operations
  • Aligning tracer platforms with GLP standards and regulators to speed adoption in obesity research
12:55 - 13:00
Q&A SESSION ON METABOLIC TRACERS IN OBESITY RESEARCH
13:00 - 13:30
RESERVED PRESENTATION
13:30 - 13:45
FEEDBACK & RAFFLE DRAW
13:45 - 15:00
NETWORKING LUNCH

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.